In the past decade, a number of molecules with antitumor activity targeting proteins involved in melanoma pathogenesis [81], with particular reference to BRAF mutant inhibitors (such as dabrafenib or encometinib) administered in combination with MEK inhibitors (trametinib or binimetinib, respectively) are successfully introduced into the clinical practice [82]. This evidence concerns the gene BRAF and melanoma.